Although the cure rates for pediatric and adolescent cancer continue to increase, many solid tumor malignancies continue to have overall worse outcomes when compared to acute lymphoblastic leukemia and lymphomas. This is especially true for metastatic or recurrent solid tumors. Immunotherapy may impact how we treat these tumors. Although the number of immunotherapy clinical trials in pediatric patients has been small compared to adults, the results are promising even in patients with advanced disease and should be explored further. In this chapter we will review the different immunotherapeutic approaches that have and are being evaluated in the pediatric oncology setting.
- Solid tumor
ASJC Scopus subject areas
- Immunology and Microbiology(all)